World Prostate Cancer Therapeutics Market

World Prostate Cancer Therapeutics Market

This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Millions. Analytics in the report specifically focuses on revenues generated from hormonal therapies.The report provides separate comprehensive analytics for US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2006 through 2015. The report profiles 138 companies including many key and niche players worldwide such as Abbott Laboratories, Æterna Zentaris Inc., ALZA Corporation, Amgen Inc., AstraZeneca PLC., Medimmune, LLC, Bristol-Myers Squibb Company, Cell Genesys Inc., Dendreon Corporation, EUSA Pharma, (USA) Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc., Immunomedics, Inc., Indevus Pharmaceuticals Inc., Novartis AG, OSI Pharmaceuticals, Inc., Paladin Labs Inc., Pfizer Inc., Progenics Pharmaceuticals, Inc., Sanofi-Aventis SA, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

PROSTATE CANCER THERAPEUTICS
A GLOBAL STRATEGIC BUSINESS REPORT MCP-1747


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Product Definitions and Scope of Study I-3
Hormonal Therapy I-3
Radiation Therapy I-4
Chemotherapy I-4
Surgical Procedures I-4
Other Treatment Options I-4


II. EXECUTIVE SUMMARY

1. Industry Overview II-1
A Prelude II-1
New Products to Bolster Sales of Prostate Cancer Therapeutics II-1
Key Prostate Cancer Drugs & Companies II-2
Hormone Therapies to Dominate Global Prostate Cancer
Therapeutics Market II-2
Table 1: Sales of FDA Approved Prostate Cancer Hormonal
Therapy Drugs in the US for 2007 (includes corresponding
Graph/Chart) II-2
Select Prostate Cancer Hormonal Therapy Drugs with Year of
FDA Approval II-3
Targeted Therapy - The New Frontier of Cancer Treatment II-3
Radiotherapy - Gaining Prominence II-3
Innovations in Drug Delivery: A Key Factor in Product
Differentiation II-4
New Therapies Appear Over the Horizon II-4
New Generation Prostate Cancer Drugs and Their Area of Use II-4
Small Cap Companies: A Target of Private Capital Financing II-5
Drugs (that are both available and under pipeline) Developed
by the Three Small-Cap Companies II-5
Minimally Invasive Devices Likely to Get Good Reception in
Emerging Markets II-5
Awareness Drives European Prostate Cancer Therapeutics Market II-6
Growth Drivers II-6
Rise in Prostate Cancer Incidences & Access to Modern
Therapeutics Foster Growth II-6
Table 2: New Incidences of Prostate Cancer (in ‘000)
Worldwide for the years 2004 through 2007 (includes
corresponding Graph/Chart) II-6

Table 3: New Cancer Cases Diagnosed in the US in 2007:
Percentage Share by Leading Cancer Sites (includes
corresponding Graph/Chart) II-7
Demographics & Lifestyles Raise the Risk of Prostate Cancer II-7
Table 4: Probability of Developing Invasive Prostate Cancer
by Age Group in the US (includes corresponding Graph/Chart) II-7

Table 5: Male Population by Age Group in the US for the year
2007 (includes corresponding Graph/Chart) II-8
Select General Risk Factors and their Relative Risk Rate in
Prostate Cancer II-8
Unmet Needs Leave Scope for Further Research and Development II-8
Supportive Cancer Drugs Contribute to Growth II-8
Select FDA Approved Drugs for Palliative Treatment of
Advanced Prostate Cancer II-9
Improved Screening, Diagnosis & Patient Survival Rates
Trigger Growth II-9
Table 6: Five-Year Prostate Cancer Survival Rate in the US
by Race, 1975-2002 (includes corresponding Graph/Chart) II-9

Table 7: Five-Year Cancer Survival Rate Among US Males by
Type - Prostate and Testis (1996-2002) (includes
corresponding Graph/Chart) II-10

Table 8: Five-Year Cancer Survival Rate (%) in the US by
Race, 1996-2003 (includes corresponding Graph/Chart) II-10
Molecular Imaging of Cancer: Critical in Improving Patient
Outcomes II-11
Growth Restraints II-11
Limited Tumor Specificity and Toxicity II-11
Complicated Treatment Protocols: A Major Stumbling Block in
Patient Compliance II-11
Multiple Drug Resistance II-12
Stringent Regulations Delay Market Approval II-12
Ongoing Clinical Trials in Hormone Refractory Prostate Cancer II-12
Challenges Encountered in Clinical Trials II-12
Notable Prostate Cancer Drug Failures in Phase III Development II-13
High Development Costs Retracts Manufacturers in Developing
Countries II-13

2. Clinical Trials II-14
Drugs in Pipeline II-14
Select Prostate Cancer Drugs/Compounds in Pipeline II-14
Select Prostate Cancer Drugs Under Phase II/III Trials by
Leading Companies II-15
Drugs in Pre-Clinical Stage II-16
Select Prostate Cancer Drugs/Compounds in Pre-Clinical Stage II-16
Commercially Available Drugs II-16
Select Prostate Cancer Drugs (Commercially Available) by
Leading Companies II-16

3. Product Overview II-17
Cancer: A Major Health Crises in the Modern World II-17
Table 9: Mortality Rate in the US for the Year 2005 by
Ailment - Heart Diseases, Cancer, Cerebrovascular Diseases,
Chronic Lower Respiratory Diseases, and Accidents
(Unintentional Injuries) (includes corresponding Graph/Chart) II-17

Table 10: Mortality Rate in the US for the Year 2005:
Percentage Breakdown by Cause of Death -Heart Diseases,
Cancer, Cerebrovascular diseases, Chronic lower respiratory
diseases, Accidents (unintentional injuries), and Others
(includes corresponding Graph/Chart) II-17

Table 11: Cancer Death Rates in the US (2007): Percentage
Breakdown by Cancer Type - Lung & Bronchus, Prostate, Colon &
Rectum, Pancreas, Leukemia, and Others (includes
corresponding Graph/Chart) II-18

Table 12: Comparison of Mortality Among African Americans and
Whites by Cancer Type in the US, 2000- 2004 (includes
corresponding Graph/Chart) II-18
Prostate - Structure II-18
Pituitary Gland II-19
Testes II-19
Prostate Cancer - A Primer II-20
Key Facts to Gaze at II-20
Table 13: Lifetime Probability of Developing Cancer (in Men)
by Type in the US, 2002-2004 II-20

Table 14: New Incidences of Prostate Cancer (in ‘000)
Worldwide for the years 2007 and 2008 (includes
corresponding Graph/Chart) II-21
Table 15: Mortality Due to Prostate Cancer (in ‘000)
Worldwide for the Years 2007 and 2008 (includes
corresponding Graph/Chart) II-22
Table 16: Male Population (in Million) for the Year 2007 for
Select Regions (includes corresponding Graph/Chart) II-23
Screening/Detection of Prostate Cancer II-24
Digital Rectal Exam (DRE) II-24
Transrectal Ultrasound (TRUS) II-24
PSA Blood Test II-24
Strategies to Enhance Screening/Detection of Prostate Cancer II-24
Improved PSA Testing II-25
Total PSA, Free PSA and PSA-Alpha-1-Protease Inhibitor Levels II-25
Insulin-like Growth Factor (IGF-1) and Intact IGF- Binding
Protien-3 (IGF-BP3) II-25
GSTP1 Methylation Levels and Prostate Cancer Diagnosis II-25
Microbubble Ultrasound II-26
Staging of Prostate Cancer II-26
Gleason Score II-27
Gleason Score and Grading of Prostate Cancer II-27
TNM Staging II-27
T-Staging Analysis of Prostate Cancer II-27
Genetic & Non-Genetic Factors II-28
Hereditary or Genetic Factors II-28
Non-Genetic or Environmental Factors II-28
Table 17: Prostate Cancer Incidence/Mortality Rate by Race &
Ethnicity in US, 1999-2003 (includes corresponding
Graph/Chart) II-29
Prevention of Cancer II-30
Role of Diet in Prostate Cancer II-30

4. Treatment Options for Prostate Cancer II-32
Hormonal Therapy II-32
Medical Hormone Therapy II-32
LHRH Analogs II-33
Dose of LHRH Agonists for Advance Prostate Carcinoma Treatment II-33
Anti-Androgens II-34
Leading Non-Steroidal Anti-androgen Hormonal Therapy Drugs
for Prostate Cancer II-34
Anti-Androgen Monotherapy II-34
Orchiectomy II-35
Side Effects of Orchiectomy II-35
Time to Start Hormonal Therapy II-35
Strategies to Enhance Hormonal Treatment II-36
Combination Therapy II-36
Intermittent Therapy II-36
Radiation Therapy II-36
Brachytherapy II-36
Treatment Procedure II-37
Benefits of Brachytherapy II-38
Drawbacks of Brachytherapy II-38
High Dose Rate (HDR) Brachytherapy II-39
External Beam Radiation Therapy (EBRT) II-39
Side Effects of Radiotherapy II-39
Strategies to Enhance Radiation Treatment II-39
New Radiation Techniques II-39
Whole Pelvic Radiation Therapy (WPRT) II-40
New Radiation Devices II-40
Chemotherapy II-40
Risks Associated with Chemotherapy II-41
Surgical Procedures for Prostate Cancer II-41
Transurethral Resection of the Prostate (TURP) II-41
Prostatectomy and Lymph Node Dissection II-42
Radical Prostatectomy II-42
Cryosurgery II-43
Advantages of Cryosurgery II-43
Disadvantages of Cryosurgery II-43
Other Treatment Options II-43
Intensity Modulated Radiation Therapy (IMRT) II-43
Benefits of IMRT II-44
Drawbacks of IMRT II-44
Androgen Deprivation Therapy (ADT) II-44
High Dose Radiation (HDR) Monotherapy II-45
Drawbacks of HRD II-45
Choosing the Optimal Treatment Method II-45
Recurrent Prostate Cancer II-46
Recurrent Prostate Cancer Subsequent to Surgery II-46
Recurrent Prostate Cancer Subsequent to Radiation Therapy II-47
Hormone-Refractory Prostate Cancer (HRPC) II-47
Select Drugs in Advanced Development Stage for Hormone-
Refractory Prostate Cancer II-47
Chemotherapy II-47
TCaxotere® (Docetaxel) II-48
Bone Complication Treatments II-48
Bisphosphonate Drugs II-48
Doxazosin, a Cytotoxic Drug for Prostate Cancer II-49
Radiation Therapy II-49
Strategies to Enhance Recurrent Prostate Cancer Treatment II-49
Chemotherapy - New Regimens II-49
Phase I Clinical Trials II-50
Combination Therapy II-50
Gene Therapy II-50
Targeted Therapy II-50
Selective Endothelia A Receptor Antagonist - (SERA™) II-51
Other Select Targeted Therapies II-52
Tyrosine Kinase Inhibitors II-52
Anti-Angiogenic Drugs II-52
Monoclonal Antibodies II-52
Vaccines II-52
Radioactive Monoclonal Antibodies II-52

5. Drug Approvals and Clinical Studies II-53
Debiopharm Unveils Results of Phase III Study of Trelstar in
Prostate Cancer Treatment II-53
Algeta to Start Clinical Study of Alpharadin in HRPC II-53
Ferring Receives FDA Approval for Degarelix in Prostate Cancer II-53
Isis and OncoGenex Reveals Positive results of OGX- 011
Molecule in HRPC II-53
Antisoma Completes Phase 2 Study of ASA404 in Prostate Cancer II-53
Cougar Conducts Phase I/II Clinical Trials on CB7630 in
Patients with Prostate Cancer II-54
Ambrilia Unveils Results of PCK3145 in Patients with
Metastatic Prostate Cancer II-54
Peregrine Pharmaceuticals Reveals Pre-Clinical Data on
Bavituximab in Prostate Cancer II-54
Cell Genesys Reveals Data of GVAX Immunotherapy for Treatment
of Prostate Cancer II-54
Bioponic Phytoceuticals Unveils Pre-Clinical Data on
Curecumin™ for Prostate Cancer II-55
New Study Reveals Cough Medicine - Noscapine to be Effective
in Prostate Cancer II-55
Fosamax® Found Effective in Preventing Bone Loss in Prostate
Cancer Patients II-55
Genta Unveils Results of Phase II Clinical Trial of Genasense®
in Prostate Cancer II-55
Cell Therapeutics Reveals Phase 2 Clinical Trial Results of
XYOTAX™ in Androgen Independent Prostate Cancer Patients II-56
Sanofi-Aventis’ Taxotere® Enhances Survival in Metastatic
Prostate Cancer Patients II-56
NCI Initiates Phase 2 Clinical Trial of Cytogen’s QUADRAMET
for HRPC II-56
Cleveland BioLabs to Initiate Phase II Clinical Trial for
Curaxin in HRPC II-57
NeoRx Begins Clinical Study for Picoplatin in Prostate Cancer II-57
Novacea Starts Phase III Clinical Trial for Treatment of
Prostate Cancer II-57
Next Pharmaceuticals’ Supplement Nexrutine Help Prevent
Prostate Cancer II-57
Antisoma Reveals Results from AS1404 Phase II Clinical Trial
in HRPC II-57
Marshall Edwards Conducts Study on Phenoxodiol in Prostate Cancer II-58
Combination of Provenge® and Taxotere® Offer Better Results
for HRPC Patients II-58
Ambrilia Reveals Results of PSP-94 Immunoassay Study for
Cancer Therapy II-58
University of California’s Analyses Support Dendreon’s Active
Cellular Immunotherapy II-59
Spectrum Announces Positive Outcome of Satraplatin Trial on
HRPC Patients II-59
Panacea Pharmaceuticals Identifies Blood Protein for Early
Prostate Cancer Detection II-60
Active Biotech Reveals Results of TASQ Phase I Study for
Prostate Cancer II-61
Positive Results of Combined Hormone and Radiation Therapies
in Locally Advanced Prostate Cancer II-61
Positive Results from Use of IMRT in Localized Prostate Cancer II-61
Balanced Intake of Omega-6 and Omega-3 Fatty Acids Found to
Reduce Prostate Cancer Growth II-62
Sanofi’s Taxotere Gains Approval from Nice of UK for Use in
Late-Stage Prostate Cancer II-62
Protox Gains Clearance from FDA to Conduct Phase I Trial of
PRX302 II-63
Æterna Zentaris’s Ozarelix Phase II Trial Shows Positive Results II-63
Biomira Announces Results of Stimuvax Phase 2 Clinical Study II-64
Cytogen Receives FDA Clearance for CYT-500 IND Application II-64
US Researchers Unveils New Therapeutic Cancer Vaccine For
Metastatic Prostate Cancer II-64
PNNL and IsoRay Develops Cesium-131 Seed for Treatment of
Prostate Cancer II-65

6. Product Innovations/Introductions II-66
Speciality European Pharma Introduces Plenaxis II-66
Actavis Unveils Bicalutamide Tablets for Prostate Cancer in
the European Markets II-66
Artemis to Introduce IGRT II-66
Immunomedics Introduces Immunotoxin for Treatment of Prostate
and Lung Cancer II-66
Barr Unveils Generic Version of Proscar® Tablets II-67
IRX Therapeutics to Develop Vaccine for Prostate Cancer II-67
Actavis Introduces New Generic Drugs in Europe II-67
Robot-Assisted Radical Prostatectomy for Treatment of Prostate
Cancer II-67

7. Recent Industry Activity II-68
Sanofi-Aventis Secures Approval of Japanese Health Ministry
for Taxotere® Injection II-68
Schering-Plough Terminates Collaboration with Novacea II-68
Takeda Terminates JV Deal, Merges its Subsidiaries II-68
Aureon Laboratories and Pfizer Announce Research Partnership II-68
Celera Enters into Licensing Agreement with Merck II-69
Celera Announces Demerger from Applera Corporation II-69
GPC Biotech and Celgene Terminate Agreement for Satraplatin II-70
EUSA Acquires Cytogen Corporation II-70
Eisai Acquires MGI Pharma II-70
BN ImmunoTherapeutics Enters into a Scientific Partnership
with NCI II-70
Morphotek® Enters into Licensing Agreement with NCI II-71
ValiRx Acquires Exclusive Evaluation License from CRT for New
Prostate Cancer Compound II-71
Cell Genesys Forms Global Alliance with Takeda on GVAX
Immunotherapy Development for Prostate Cancer II-71
Sirnaomics Extends Partnership with GRL to Develop Multi-
Targeted RNAi Therapeutic Products II-72
Aureon and Pfizer to Collaborate on New Stage of Research Project II-72
CancerPartners UK Collaborates with Spire Healthcare II-72
Cougar Biotech Enters into an Agreement with US FDA II-73
Scottish Scientists Receives Contract from Cancer Research UK II-73
ValiRx Collaborates with University of Surrey on Prostate
Cancer Diagnostics II-73
ValiRx Subsidiary Extends Collaboration with Cancer Research
Technology II-73
MacroArray Partners with Abbott on PCADM-1 Test for Prostate
Cancer II-74
Novacea Enters into Agreement with Schering-Plough II-74
Bayer to Stop Sale of Viadur - A Drug for Prostate Cancer II-74
Sagemark Embarks on Radiation Therapy Venture II-75
RTS Concludes Californian Radiation Therapy Center Acquisition II-75
Radiation Therapy Takes Over a North Carolina Treatment Center II-75
DRAXIMAGE and Med Discovery Enter into Research Collaboration II-75
Core Oncology Completes Acquisition of Coloplast’s
Brachytherapy Business II-76
Novacea Licenses Asenstar Prostate Cancer Drug to Schering-Plough II-76
Bentley Receives Approval for Generic Version of Casodex II-76
GSK Acquires Praecis Pharmaceuticals II-77
Samaritan Acquires Metastatin Pharma II-77
Champions Biotechnology Acquires Patent Rights for Potential
Cancer Treatments II-77
GPC Biotech Submits NDA for Treatment of Prostate Cancer II-77
MedMira Inks Agreement to Take Over Rights of a New Marker
Technology II-78
Cell Genesys’s GVAX Prostate Cancer-Treatment Attains FDA’s
Fast Track Tag II-78
Envisioneering Medical Enters into Agreement with BrachySciences II-78
Signet Enters into Agreement with AsymmetRx to Distribute ‘
Prostate-63’ Tests II-79
Mylan Pharmaceuticals Obtains FDA Approval for Finasteride’s ANDA II-79
Æterna Zentaris Enters into Agreement with Nippon Kayaku II-79
Progenics Pharmaceuticals Broadens Association with Seattle
Genetics II-80
Diosynth and Dendreon Sign Multi-Year Commercial Supply Deal II-80
Genstar Capital Completes Acquisition of OnCure II-80
Generex Biotechnology Expands Antigen Express Cancer Trials II-80
Progenics Pharmaceuticals Acquires PSMA Development Company II-81
Schweizerhall Acquires Novosis II-81
Misonix Expands into France with Sonablate® 500 II-81
Indevus Enters into Agreement to Takeover Valera II-82
Oncobionic Receives FDA Clearance for Cancer Treatment Technology II-82
Misonix Expands HIFU Business in Europe by Entering into Spain II-82
Altana Divests Entire Stake in GPC Biotech II-83
Ipsen Enters into Partnership with GTx to Develop and Market
Acapodene in Europe II-83
Egenix and Proteome Systems Collaborate to Develop Prostate
Cancer Test Using Semen II-83
Valera and Spepharm Partner to Market Vantas, and Supprelin-LA II-84
SurModics and AbbeyMoor Collaborate to Develop Products to
Treat Prostate Diseases II-84
Dendreon Constructs Manufacturing Facility in New Jersey II-84
MediGene Introduces Prostate Cancer Drug in Italian Market II-85
Gen-Probe Introduces Innovative Test for Prostate Cancer in
Europe II-85
DRL Introduces Generic Version of Proscar II-85
Ferring Partners with Astellas on Degarelix License for
Prostate Cancer Treatment II-85
Protox Acquires PRX321 Cancer Program from US Public Health
Service and Neurocrine II-86
Astex Collaborates with CRT and Newcastle University for New
Drug Discovery II-86
Miraculins and Duke University Enter into Collaboration II-86
Bayer Receives Rights to Prostate Cancer and Transplantation
Drug Test from Abbott II-86
Encorium Group Signs Contract with Global Biopharmaceutical
Company II-86
Paladin Signs an Agreement with Watson for Supply and Sale of
Trelstar® II-87
BioWa Obtains License for Anti-FGF8 Antibody from Kyowa Hakko II-87
OncoGenex and Isis Pharmaceuticals Expand Partnership II-87
Caprion and AstraZ eneca Enter into Collaboration II-88
Innovate Oncology and Prostagenics Enter into Capridine- Beta
Development Agreement II-88
Protein Design Labs Sublicenses Antibody-Drug Conjugates
Development Rights to Genentech II-88
National Cancer Institute Enters into Agreement with Illumina II-89
Sosei Seeks Marketing Rights for Prostate Cancer Drug in Japan II-89

8. Focus on Select Global Players II-90
Abbott Laboratories (USA) II-90
Æterna Zentaris Inc. II-90
ALZA Corporation (USA) II-90
Amgen Inc. (USA) II-91
AstraZeneca PLC (UK) II-91
Medimmune, LLC (USA) II-92
Bristol-Myers Squibb Company (USA) II-92
Cell Genesys Inc. (USA) II-92
Dendreon Corporation (USA) II-93
EUSA Pharma, (USA) Inc. (USA) II-93
F. Hoffmann-La Roche Ltd. (Switzerland) II-94
Genentech Inc. (USA) II-94
GlaxoSmithKline Plc (UK) II-95
Immunomedics, Inc. (USA) II-95
Indevus Pharmaceuticals Inc. (USA) II-95
Novartis AG (Switzerland) II-96
OSI Pharmaceuticals, Inc. (USA) II-96
Paladin Labs Inc. (Canada) II-97
Pfizer Inc. (USA) II-97
Progenics Pharmaceuticals, Inc. (USA) II-97
Sanofi-Aventis SA (France) II-98
Spectrum Pharmaceuticals, Inc. (USA) II-98
Takeda Pharmaceutical Company Limited (Japan) II-98

9. Global Market Perspective II-100
Table 18: World Recent Past, Current & Future Analysis for
Prostate Cancer Therapeutics by Geographic Region/ Country -
US, Europe, and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart) II-100

Table 19: World 10-Year Perspective for Prostate Cancer
Therapeutics by Geographic Region/Country - Percentage
Breakdown of Dollar Sales for US, Europe, and Rest of World
Markets for Years 2006, 2009 & 2015 (includes corresponding
Graph/Chart) II-101


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Overview III-1
A Surging US Prostate Cancer Therapeutics Market III-1
Table 20: Probability of Developing Invasive Prostate
Cancer by Age Group in the US (includes corresponding
Graph/Chart) III-1

Table 21: Male Population by Age Group in the US for the
Year 2007 (includes corresponding Graph/Chart) III-2
Cost of Cancer Drugs - A Major Concern in the US III-2
Market Accelerators III-2
Market Challenges III-3
Market Inhibitors III-3
Table 22: Sales of FDA Approved Prostate Cancer Hormonal
Therapy Drugs in the US for 2007 (includes corresponding
Graph/Chart) III-3
Current and Future Analysis III-3
Key Statistics III-4
Table 23: Mortality Rate in the US for the Year 2005 by
Ailment - Heart Diseases, Cancer, Cerebrovascular Diseases,
Chronic Lower Respiratory Diseases, and Accidents
(Unintentional Injuries) (includes corresponding
Graph/Chart) III-4

Table 24: Mortality Rate in the US for the Year 2005:
Percentage Breakdown by Cause of Death -Heart Diseases,
Cancer, Cerebrovascular diseases, Chronic lower respiratory
diseases, Accidents (unintentional injuries), and Others
(includes corresponding Graph/Chart) III-4

Table 25: Cancer Death Rates in the US (2007): Percentage
Breakdown by Cancer Type - Lung & Bronchus, Prostate, Colon
& Rectum, Pancreas, Leukemia, and Others (includes
corresponding Graph/Chart) III-4

Table 26: New Cancer Cases Diagnosed in the US in 2007:
Percentage Share by Leading Cancer Sites (includes
corresponding Graph/Chart) III-5

Table 27: New Cases of Prostate Cancer Diagnosed in the US:
Breakdown by Leading States for the Years 2007 and 2008
(includes corresponding Graph/Chart) III-5

Table 28: Mortality Due to Prostate Cancer in the US:
Breakdown by Leading States for the Years 2007 and 2008
(includes corresponding Graph/Chart) III-6

Table 29: Lifetime Probability of Developing Cancer (in
Men) by Type in the US, 2002-2004 III-6

Table 30: Comparison of Mortality Among African Americans
and Whites by Cancer Type in the US, 2000-2004 (includes
corresponding Graph/Chart) III-7

Table 31: Five-Year Prostate Cancer Survival Rate in the US
by Race, 1975-2002 (includes corresponding Graph/Chart) III-7

Table 32: Five-Year Cancer Survival Rate Among US Males by
Type - Prostate and Testis (1996-2002) (includes
corresponding Graph/Chart) III-8

Table 33: Five-Year Cancer Survival Rate (%) in the US by
Race, 1996-2003 (includes corresponding Graph/Chart) III-8
Table 34: Prostate Cancer Incidence/Mortality Rate by Race
& Ethnicity in US, 1999-2003 (includes corresponding
Graph/Chart) III-9
Clinical Trials III-9
Product Launches III-19
Strategic Corporate Developments III-19
Select Players III-32
B.Market Analytics III-41
Table 35: US Recent Past, Current & Future Analysis for
Prostate Cancer Therapeutics Market with Annual Sales
Figures in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-41

2. Europe III-42
A.Market Analysis III-42
Overview III-42
Awareness Drives European Prostate Cancer Therapeutics Market III-42
Table 36: New Cases of Prostate Cancer Diagnosed in
Europe: Breakdown by Region/Country for the Years 2007 and
2008 (In ‘000) (includes corresponding Graph/Chart) III-42

Table 37: Mortality Due to Prostate Cancer in Europe:
Breakdown by Region/ Country for the Years 2007 and 2008
(In ‘000) (includes corresponding Graph/Chart) III-43
Current and Future Analysis III-43
Clinical Trial III-43
Product Launches III-44
Strategic Corporate Developments III-44
B.Market Analytics III-46
Table 38: European Recent Past, Current & Future Analysis
for Prostate Cancer Therapeutics by Geographic
Region/Country - France, Germany, Italy, United Kingdom,
Spain, and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart) III-46

Table 39: European 10-Year Perspective for Prostate Cancer
Therapeutics by Geographic Region/Country - Percentage
Breakdown of Dollar Sales for France, Germany, Italy, United
Kingdom, Spain, and Rest of Europe Markets for Years 2006,
2009 & 2015 (includes corresponding Graph/Chart) III-47

2a. France III-48
A.Market Analysis III-48
Overview III-48
Anti-Androgen and LHRH Analogs Drive the French Market III-48
Current and Future Analysis III-48
Clinical Trials III-48
Strategic Corporate Developments III-49
Select Players III-50
B.Market Analytics III-51
Table 40: French Recent Past, Current & Future Analysis for
Prostate Cancer Therapeutics Market with Annual Sales
Figures in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-51

2b. Germany III-52
A.Market Analysis III-52
Current and Future Analysis III-52
Product Launch III-52
Strategic Corporate Developments III-52
GPC Biotech AG - A Major Player III-54
B.Market Analytics III-54
Table 41: German Recent Past, Current & Future Analysis for
Prostate Cancer Therapeutics Market with Annual Sales
Figures in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-54

2c. Italy III-55
A.Market Analysis III-55
Italian Prostate Cancer Therapeutics Market - An Overview III-55
Current and Future Analysis III-55
Clinical Trial III-55
Strategic Corporate Development III-55
B.Market Analytics III-56
Table 42: Italian Recent Past, Current & Future Analysis for
Prostate Cancer Therapeutics Market with Annual Sales
Figures in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-56

2d. The United Kingdom III-57
A.Market Analysis III-57
Overview III-57
LHRH Analogs - The Market Driver III-57
Current and Future Analysis III-57
Clinical Trials III-57
Product Launch III-58
Strategic Corporate Developments III-58
Select Players III-60
B.Market Analytics III-62
Table 43: UK Recent Past, Current & Future Analysis for
Prostate Cancer Therapeutics Market with Annual Sales
Figures in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-62

2e. Spain III-63
A.Market Analysis III-63
Overview III-63
Spanish Prostate Cancer Therapeutics Market - On a Roll III-63
Current and Future Analysis III-63
Strategic Corporate Developments III-63
B.Market Analytics III-64
Table 44: Spanish Recent Past, Current & Future Analysis for
Prostate Cancer Therapeutics Market with Annual Sales
Figures in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-64

2f. Rest of Europe III-65
A.Market Analysis III-65
Current and Future Analysis III-65
Clinical Trials III-65
Strategic Corporate Development III-65
Select Players III-66
B.Market Analytics III-67
Table 45: Rest of Europe Recent Past, Current & Future
Analysis for Prostate Cancer Therapeutics Market with Annual
Sales Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) III-67

3. Rest of World III-68
A.Market Analysis III-68
Current and Future Analysis III-68
A Peek into Canadian Market III-68
Table 46: New Cases of Prostate Cancer Diagnosed in Canada
(2008): Breakdown by Leading Province (includes
corresponding Graph/Chart) III-68

Table 47: Mortality Due to Prostate Cancer Diagnosed in
Canada (2008): Breakdown by Leading Province (includes
corresponding Graph/Chart) III-68

Table 48: Prostate Cancer Market in Canada (2008): New
Cases and Deaths Due to Prostate Cancer by Age Group III-69
Ambrilia Unveils Results of PCK3145 in Patients with
Metastatic Prostate Cancer III-69
Ambrilia Reveals Results of PSP-94 Immunoassay Study for
Cancer Therapy III-69
Select Canadian Players III-70
A Glance into Other Select Markets III-71
Minimally Invasive Devices Likely to Get Good Reception in
Emerging Markets III-71
Cancer Market in Asia III-72
Australia III-72
India III-72
Japan III-72
Malaysia III-73
Table 49: New Cases of Prostate Cancer Diagnosed in
Asia-Pacific: Breakdown by Region/Country for the Years
2007 and 2008 (includes corresponding Graph/Chart) III-73

Table 50: Mortality Due to Prostate Cancer in
Asia-Pacific: Breakdown by Region/ Country for the Years
2007 and 2008 (includes corresponding Graph/Chart) III-73
Cancer Market in Latin America III-74
Brazil III-74
Mexico III-74
Argentina III-74
Table 51: New Cases of Prostate Cancer Diagnosed in Latin
America: Breakdown by Region/Country for the Years 2007
and 2008 (includes corresponding Graph/Chart) III-74

Table 52: Mortality Due to Prostate Cancer in Latin
America: Breakdown by Region/ Country for the Years 2007
and 2008 (includes corresponding Graph/Chart) III-75
Clinical Trial III-75
Product Launch III-75
Strategic Corporate Developments III-76
Select Players III-78
B.Market Analytics III-79
Table 53: Rest of World Recent Past, Current & Future
Analysis for Prostate Cancer Therapeutics Market with Annual
Sales Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) III-79


IV. COMPETITIVE LANDSCAPE